ViaCyte Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ViaCyte Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2800
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ViaCyte Inc (ViaCyte), formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes. The company’s pipeline products portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing beta cell function; and PEC-Direct, for type 1 diabetes patients that have glycemic lability, hypoglycemic episodes, and impaired hypoglycemia awareness. Its PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device. The company works in partnership with academic, commercial and not-for-profit institutions. ViaCyte is headquartered in San Diego, California, the US.

ViaCyte Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ViaCyte Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
Partnerships 14
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 14
Licensing Agreements 15
ViaCyte Enters into Licensing Agreement with Janssen Biotech 15
Takara Bio Enters into Licensing Agreement with ViaCyte 16
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 17
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 18
ViaCyte Inc – Key Competitors 19
ViaCyte Inc – Key Employees 20
ViaCyte Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Government and Public Interest 22
Apr 17, 2018: ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells 22
Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 23
Product News 24
05/22/2017: JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes 24
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Direct for Type 1 Diabetes 25
02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Encap for insulin-requiring diabetes 26
Product Approvals 27
May 22, 2017: ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes 27
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
ViaCyte Inc, Pharmaceuticals & Healthcare, Key Facts 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ViaCyte Raises USD10 Million in Financing 11
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12
ViaCyte Raises USD15 Million in Venture Financing 13
ViaCyte Enters into Research Agreement with W. L. Gore & Associates 14
ViaCyte Enters into Licensing Agreement with Janssen Biotech 15
Takara Bio Enters into Licensing Agreement with ViaCyte 16
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 17
Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 18
ViaCyte Inc, Key Competitors 19
ViaCyte Inc, Key Employees 20
ViaCyte Inc, Subsidiaries 21

List of Figures
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[ViaCyte Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cara Therapeutics Inc (CARA):製薬・医療:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • KEB Hana Bank:企業の戦略・SWOT・財務情報
    KEB Hana Bank - Strategy, SWOT and Corporate Finance Report Summary KEB Hana Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Unico Sigorta A.S:企業の戦略・SWOT・財務分析
    Unico Sigorta A.S - Strategy, SWOT and Corporate Finance Report Summary Unico Sigorta A.S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • Gland Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Gland Pharma Ltd (Gland Pharma) is a healthcare products provider that develops and manufactures active pharmaceutical ingredients. The company’s products include injectables, pre filled syringes, vials, ampoules, infusions, ophthalmic solutions, lyophilized vials, dry powders, lyophilized p …
  • Montana Tech Components AG:企業の戦略・SWOT・財務情報
    Montana Tech Components AG - Strategy, SWOT and Corporate Finance Report Summary Montana Tech Components AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • MorphoSys AG (MOR):企業の財務・戦略的SWOT分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, and research applications. The company’s pipeline products include MOR208, MOR103, MOR202, MAA868, VAY736, MOR106, and MOR107. Its drugs are used for the treatment of various types of cancers, psoriasis, rheuma …
  • TFS International AB:製薬・医療:M&Aディール及び事業提携情報
    Summary TFS International AB (TFS International) is a contract research organization that provides clinical development solutions. The organization through its business areas, TFS Develop and TFS People, provides various services worldwide including clinical development planning, regulatory affairs, …
  • Terumo Corp (4543):企業の製品パイプライン分析2018
    Summary Terumo Corp (Terumo) is a medical technology company, which manufactures and sells a wide range of medical care products including hospital and medical products, and equipment. Its major product categories include vascular interventional products, cardiovascular surgical systems, artificial …
  • Aveda Transportation and Energy Services Inc (AVE):石油・ガス:M&Aディール及び事業提携情報
    Summary Aveda Transportation and Energy Services Inc (Aveda), formerly Phoenix Oilfield Hauling Inc is an oilfield service provider that offers energy transportation and other energy related services. The company provides specialized transportation services and equipment for drilling, exploration, d …
  • Biolife Solutions Inc (BLFS):企業の財務・戦略的SWOT分析
    Summary BioLife Solutions Inc (BioLife Solutions) is a developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues. The company offers serum-free and protein-free solutions, which are formulated to red …
  • Pfizer Inc (PFE):企業の財務・戦略的SWOT分析
    Pfizer Inc (PFE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Pioneer Hi-Bred International Inc:企業のM&A・事業提携・投資動向
    Pioneer Hi-Bred International Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pioneer Hi-Bred International Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Glanbia Nutritionals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Glanbia Nutritionals Inc (Glanbia Nutritionals) is a global provider of nutritional ingredients, functional ingredients, and customized premix solutions. The company manufactures and markets customized micronutrient blends, vitamins, minerals, amino acids, colors and specialty ingredients. T …
  • African Phoenix Investments Ltd:企業の戦略・SWOT・財務分析
    African Phoenix Investments Ltd - Strategy, SWOT and Corporate Finance Report Summary African Phoenix Investments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Scomi Group Bhd (SCOMI):企業の財務・戦略的SWOT分析
    Scomi Group Bhd (SCOMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Actinium Pharmaceuticals Inc (ATNM):企業の財務・戦略的SWOT分析
    Summary Actinium Pharmaceuticals Inc (Actinium), formerly Cactus Ventures Inc, is a biopharmaceutical company. It develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company's pipeline products include Iomab- …
  • Kohl’s Corporation (KSS):企業の財務・戦略的SWOT分析
    Kohl's Corporation (KSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Galp Energia SGPS SA (GALP):電力:M&Aディール及び事業提携情報
    Summary Galp Energia SGPS SA (Galp) is an integrated energy company. It explores for, develops and produces crude oil and natural gas, refines crude oil, and markets refined petroleum products. The company also conducts power generation, produces biodiesel and trades gas. It imports, transports and …
  • Novartis AG (NOVN):企業の財務・戦略的SWOT分析
    Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆